The estimated Net Worth of Adam R Craig is at least $1.55 Million dollars as of 24 January 2023. Adam Craig owns over 85,317 units of Sunesis Pharmaceuticals Inc stock worth over $167,883 and over the last 13 years he sold SNSS stock worth over $20,432. In addition, he makes $1,361,030 as Executive Vice President - Development and Chief Medical Officer at Sunesis Pharmaceuticals Inc.
Sign up
Adam Craig SNSS stock SEC Form 4 insiders trading
Adam has made over 9 trades of the Sunesis Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 85,317 units of SNSS stock worth $71,666 on 24 January 2023.
The largest trade he's ever made was exercising 242,300 units of Sunesis Pharmaceuticals Inc stock on 9 November 2022 worth over $203,532. On average, Adam trades about 35,042 units every 128 days since 2012. As of 24 January 2023 he still owns at least 31,557 units of Sunesis Pharmaceuticals Inc stock.
You can see the complete history of Adam Craig stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Adam Craig biography
Dr. Adam R. Craig, M.D., Ph.D., is an Executive Vice President - Development, Chief Medical Officer of Sunesis Pharmaceuticals, Inc., since March 1, 2012. From September 2007 until December 2011, Dr. Craig served as Chief Medical Officer of ChemGenex Pharmaceuticals Ltd., a biotechnology company focused on the development of novel therapeutic agents for the treatment of cancer, and in similar roles following the acquisition of ChemGenex by Cephalon, Inc. in July 2011, and the acquisition of Cephalon, Inc. by Teva Pharmaceutical Industries Ltd. in October 2011. From December 2011 until joining the Company, Dr. Craig served as a consultant to Teva Pharmaceutical Industries Ltd. Before joining ChemGenex, he was founding Chief Medical Officer at Innovive Pharmaceuticals, Inc., a hematology-focused company. Prior to joining Innovive, Dr. Craig held positions of increasing responsibility at ArQule Inc., Ilex Oncology Inc., and Antisoma plc. Dr. Craig received his medical qualifications from London University, a Ph.D. in molecular medicine from the University of Leeds, and an M.B.A. from the Open Business School in the United Kingdom. Dr. Craig is a member of the Royal College of Pediatrics and Child Health Physicians (UK) and undertook post-graduate training in pediatrics and pediatric oncology. He also currently serves as a member of the Commercialization Review Council for the Cancer Prevention Research Institute of Texas, a fund for cancer research and prevention programs and services.
What is the salary of Adam Craig?
As the Executive Vice President - Development and Chief Medical Officer of Sunesis Pharmaceuticals Inc, the total compensation of Adam Craig at Sunesis Pharmaceuticals Inc is $1,361,030. There are no executives at Sunesis Pharmaceuticals Inc getting paid more.
How old is Adam Craig?
Adam Craig is 51, he's been the Executive Vice President - Development and Chief Medical Officer of Sunesis Pharmaceuticals Inc since 2012. There are 6 older and 2 younger executives at Sunesis Pharmaceuticals Inc. The oldest executive at Sunesis Pharmaceuticals Inc is H. Ward Wolff, 71, who is the Director.
What's Adam Craig's mailing address?
Adam's mailing address filed with the SEC is 3101 WESTERN AVENUE, SUITE 800, , SEATTLE, WA, 98121.
Insiders trading at Sunesis Pharmaceuticals Inc
Over the last 19 years, insiders at Sunesis Pharmaceuticals Inc have traded over $89,557,714 worth of Sunesis Pharmaceuticals Inc stock and bought 191,253,594 units worth $84,730,221 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Peter J Barris. On average, Sunesis Pharmaceuticals Inc executives and independent directors trade stock every 67 days with the average trade being worth of $14,060,191. The most recent stock trade was executed by Tina Gullotta on 29 May 2020, trading 6,000 units of SNSS stock currently worth $1,980.
What does Sunesis Pharmaceuticals Inc's logo look like?
Complete history of Adam Craig stock trades at CTI BioPharma Corp and Sunesis Pharmaceuticals Inc
Sunesis Pharmaceuticals Inc executives and stock owners
Sunesis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Adam Craig,
Executive Vice President - Development, Chief Medical Officer -
Stephen Ketchum,
Director -
David Stump,
Independent Director -
Homer Pearce,
Independent Director -
Nicole Onetto,
Independent Director -
Matthew Fust,
Independent Director -
Steve Carchedi,
Independent Director -
H. Ward Wolff,
Director -
Tina Gullotta,
Principal Accounting Officer, Vice President - Finance -
Dayton Misfeldt,
Chief Executive Officer, Principal Financial Officer, Secretary, Director -
James Young,
Non-Executive Independent Chairman of the Board -
Eric Bjerkholt,
EVP, CFO & Corp. Secretary -
Geoffrey M. Parker,
Director -
Steven B Ketchum,
Director -
Daniel N Jr Swisher,
President and CEO -
Oncology Impact Management ...,
-
William P. Quinn,
See Remarks -
Judith A. Fox,
See Remarks -
Patrick J Kerins,
10% owner -
Ryan D Drant,
10% owner -
Forest Baskett,
10% owner -
Peter J Barris,
10% owner -
M James Barrett,
10% owner -
Equity Opportunities Fund, ...,
-
City Capital Llc Bay City C...,
-
Scott D Sandell,
10% owner -
Krishna Kittu Kolluri,
10% owner -
Helen Susan Kim,
Director -
Joseph I De Pinto,
EVP, CCO -
Biopharma Partners Iii Lpal...,
-
Equity Opportunities Fund, ...,
-
Robert Scott Mc Dowell,
Vice President, Research -
Edward Hurwitz,
Director -
Dominique Semon,
10% owner -
Biopharma Partners Iii Lpal...,
-
Iii Eugene A Trainor,
10% owner -
Charles M Linehan,
10% owner -
Equity Opportunities Fund, ...,
-
Pincus Equity Partners Lpwa...,
-
Valerie L Pierce,
Sr. VP, GC & Corp. Secretary -
Anthony B Evnin,
Director -
Steven D Goldby,
Director -
James A Wells,
Director -
Stephen P A Fodor,
Director -
Idec Incbiogen Idec Ma Inc ...,
-
Pincus Equity Partners Lpwa...,
-
Daniel C Md Adelman,
Senior VP,Drug Discovery & Dev -
Ixmayfield Ix Management Ll...,
-
Jonathan S Leff,
Director -
Daryl B Winter,
SVP,Gen Counsel/Corp Secretary -
Capital Iv, Lp Aisling Capi...,